Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 2 Gastrointestinal 2 Sarcoma 1 Plasma cell 1 Other hematologic neoplasm 1 Lymphoid 1 CNS 1

Conditions

Gliosarcoma 1 Glioblastoma 1

Interventions

Temozolomide 147 Radiotherapy 91 Cyclophosphamide 53 Magnetic Resonance Spectroscopy 43 Radiation 42 Bevacizumab 38 Irinotecan 34 Filgrastim 29 Radiosurgery 27 Specimen Handling 25 Nivolumab 25 Carboplatin 24 Topotecan 23 Etoposide 22 fludarabine 20 Surgical Procedures, Operative 20 pembrolizumab 19 Vorinostat 18 Vincristine 18 Melphalan 17 Granulocyte Colony-Stimulating Factor 17 sargramostim 15 Peripheral Blood Stem Cell Transplantation 14 Ipilimumab 14 Drug Therapy 13 temsirolimus 12 Sirolimus 12 Radiotherapy, Intensity-Modulated 12 O(6)-benzylguanine 12 Everolimus 12

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × ficlatuzumab × CNS × Clear all

NCT01189513 2012-02-20

SCH-900105 in Recurrent Glioblastoma

M.D. Anderson Cancer Center

Phase 1 Withdrawn

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡